You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Flibanserin - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for flibanserin and what is the scope of freedom to operate?

Flibanserin is the generic ingredient in one branded drug marketed by Sprout Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Flibanserin has forty-two patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for flibanserin
International Patents:42
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 74
Clinical Trials: 19
Patent Applications: 556
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in flibanserin?flibanserin excipients list
DailyMed Link:flibanserin at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for flibanserin
Generic Entry Date for flibanserin*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for flibanserin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrew McDonaldPhase 2
Mohit KheraPhase 2
Sprout Pharmaceuticals, IncPhase 2

See all flibanserin clinical trials

Pharmacology for flibanserin
Mechanism of ActionP-Glycoprotein Inhibitors

US Patents and Regulatory Information for flibanserin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for flibanserin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 ⤷  Try a Trial ⤷  Try a Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 ⤷  Try a Trial ⤷  Try a Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.